BONESUPPORT received FDA approval to launch an Investigational Device Exemption study of CERAMENT G in the treament of open diaphyseal tibial fractures, slated to start by the end of 2016.
The randomized, multicenter, controlled, 230-patient FORTIFY trial will evaluate safety and efficacy of the injectable gentamicin antibiotic-eluting bone graft substitute as part of surgical repair. BONESUPPORT intends for at least 50% of the study data to come from U.S. subjects.
At the start of 2016, BONESUPPORT announced the milestone of >20,000 patients treated worldwide with CERAMENT products. CERAMENT G received CE Mark approval and launched in the EU in 1Q13, while CERAMENT V (vancomycin-eluting) entered EU launch in early 2Q15.
BONESUPPORT received FDA approval to launch an Investigational Device Exemption study of CERAMENT G in the treament of open diaphyseal tibial fractures, slated to start by the end of 2016.
The randomized, multicenter, controlled, 230-patient FORTIFY trial will evaluate safety and efficacy of the injectable gentamicin antibiotic-eluting bone...
BONESUPPORT received FDA approval to launch an Investigational Device Exemption study of CERAMENT G in the treament of open diaphyseal tibial fractures, slated to start by the end of 2016.
The randomized, multicenter, controlled, 230-patient FORTIFY trial will evaluate safety and efficacy of the injectable gentamicin antibiotic-eluting bone graft substitute as part of surgical repair. BONESUPPORT intends for at least 50% of the study data to come from U.S. subjects.
At the start of 2016, BONESUPPORT announced the milestone of >20,000 patients treated worldwide with CERAMENT products. CERAMENT G received CE Mark approval and launched in the EU in 1Q13, while CERAMENT V (vancomycin-eluting) entered EU launch in early 2Q15.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
